Recent Finacing
Recent Raise
Aerie Pharmaceuticals develops glaucoma therapies, including AR-12286 (ROCK inhibitor improving trabecular outflow), AR-13324 (dual-mechanism agent), and conjunctival inserts for sustained ocular drug delivery.
Focus Areas
Recent Investors
Total Raised
Funding round
Investors